Journey Medical Corporation (Nasdaq:DERM), a pharmaceutical company with a focus on dermatological conditions, on Monday announced the launch and initial distribution of Emrosi, a 40 mg modified-release minocycline hydrochloride capsule, for the treatment of inflammatory lesions of rosacea in adults.

The product is available through specialty pharmacy chains.

Approved by the US Food and Drug Administration in November 2024, Emrosi is the lowest-dose oral minocycline available for rosacea treatment. Clinical trials demonstrated that Emrosi provides superior clinical outcomes compared to Oracea and placebo, while maintaining a comparable safety profile.

The first prescriptions of Emrosi have been filled.

Claude Maraoui, CEO of Journey Medical, said that the launch of Emrosi represents a major milestone for the company and reinforces its commitment to improving the quality of life for individuals with dermatological conditions.